ZMZhain Mustufvi

Zhain Mustufvi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhain Mustufvi has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Does periodontal treatment improve rheumatoid arthritis disease activity? A systematic review

    by Zhain Mustufvi, Joshua Twigg, Joel Kerry, James Chesterman, Sue Pavitt, Aradhna Tugnait, Kulveer Mankia

    What does this mean for patients? This review found 21 research trials that investigated the effect of treatment of gum disease on rheumatoid arthritis. The key finding was that treating gum disease in people who have rheumatoid arthritis improves the DAS-28, which is a measure of the severity of the rheumatoid arthritis. This is important, because rheumatoid arthritis is incurable and has a significant impact on quality of life. Furthermore, gum disease is more prevalent in people with rheumatoid arthritis and, if untreated, can lead to pain, infection and premature tooth loss. This review highlighted several limitations of the included trials. In addressing these limitations, the review makes important recommendations for future research on this topic to ensure further high-quality findings. Finally, this review makes a strong case that rheumatologists, dentists and people who are affected by rheumatoid arthritis should have a heightened awareness of the link between these two diseases. Screening and treating gum disease should form part of the normal care pathway for people with rheumatoid arthritis.


  • Open Access

    Should We Be Screening for and Treating Periodontal Disease in Individuals Who Are at Risk of Rheumatoid Arthritis?

    by Zhain Mustufvi, Stefan Serban, James Chesterman, Kulveer Mankia

    There is increasing evidence supporting an association between periodontal disease (PD) and rheumatoid arthritis (RA), both mechanistically and clinically. Trials have shown that treating PD in people with RA may improve RA disease activity. Patients with musculoskeletal symptoms without arthritis, who test positive for cyclic-citrullinated protein antibodies, are at risk of RA (CCP+ at-risk), with seropositivity preceding arthritis onset by months or years. Importantly, there is evidence to suggest that periodontal inflammation may precede joint inflammation in CCP+ at-risk and, therefore, this could be a trigger for RA. There has been increased research interest in RA prevention and the phenotyping of the pre-RA disease phase. This review will examine the merits of identifying individuals who are CCP+ at-risk and performing screening for PD. In addition, we discuss how PD should be treated once identified. Finally, the review will consider future research needed to advance our understanding of this disease association.


  • Flexible Commissioning: A prevention and access focused approach in Yorkshire and the Humber

    by Zhain Mustufvi, Olivia Barraclough, Simon Hearnshaw, Sandra Whiston, Siobhan Grant, Stefan Serban, Gail Douglas